Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Strattera Generic Name & Formulations
Legal Class
Rx
General Description
Atomoxetine HCl 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg; caps.
Pharmacological Class
Selective norepinephrine reuptake inhibitor.
How Supplied
Caps—30
Manufacturer
Generic Availability
YES
Strattera Indications
Indications
Attention deficit hyperactivity disorder (ADHD).
Strattera Dosage and Administration
Adults and Children
Swallow whole. Give once daily in the AM, or in 2 evenly divided doses (in AM and late afternoon/early PM). <6yrs: not established. Acute: ≥6yrs (≤70kg): initially 0.5mg/kg/day; increase after at least 3 days to 1.2mg/kg/day; max 1.4mg/kg or 100mg/day (whichever is less); (>70kg): initially 40mg/day; increase after at least 3 days to 80mg/day, then after 2–4 weeks may increase to max 100mg/day. Maintenance: 6–15yrs: continue with same dose, reevaluate periodically; see full labeling. Concomitant potent CYP2D6 inhibitors: titrate above initial dose at 4-week intervals only if needed. Hepatic impairment (moderate): reduce dose by 50%; (severe): reduce dose by 75%. May discontinue without tapering.
Strattera Contraindications
Contraindications
During or within 14 days of MAOIs. Narrow angle glaucoma. Pheochromocytoma or history of. Severe cardiovascular disorders that might deteriorate with clinically important increases in HR and BP.
Strattera Boxed Warnings
Boxed Warning
Suicidal ideation in children and adolescents.
Strattera Warnings/Precautions
Warnings/Precautions
Increased risk of suicidal ideation in children and adolescents. Monitor closely for clinical worsening, suicidality and unusual changes in behavior (esp. during initial therapy and dose adjustments). Severe liver injury (discontinue if jaundice or elevated liver enzymes occur; do not restart). Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Assess cardiovascular status and do physical exam. Hypertension. Tachycardia. Cardio- or cerebrovascular disease. Psychoses. Screen for bipolar disorder prior to initiation. Depression. Monitor growth, BP/pulse (esp. at baseline and after dose increases), emergence or worsening of aggressive behavior/hostility. Poor metabolizers (CYP2D6). Reevaluate periodically. Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Strattera Pharmacokinetics
See Literature
Strattera Interactions
Interactions
MAOIs: see Contraindications. May be potentiated by potent CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Increased cardiovascular effects with albuterol, pressor agents (eg, dobutamine, dopamine).
Strattera Adverse Reactions
Adverse Reactions
Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence, weight loss, dizziness, headache, mood swings, tachycardia, hypertension, orthostatic hypotension, mydriasis; rare: severe liver injury, priapism, anaphylaxis. Adults also: constipation, dry mouth, insomnia, sexual dysfunction, urinary retention/hesitation, dysuria, dysmenorrhea, hot flush.
Strattera Clinical Trials
See Literature
Strattera Note
Not Applicable
Strattera Patient Counseling
See Literature
